December 19, 2017 / 12:16 PM / 10 months ago

BRIEF-Glaukos To Begin Randomized U.S. IDE Pivotal Clinical Trial For iStent SA System

Dec 19 (Reuters) - Glaukos Corp:

* GLAUKOS TO BEGIN RANDOMIZED U.S. IDE PIVOTAL CLINICAL TRIAL FOR THE ISTENT SA™ SYSTEM

* GLAUKOS SAYS U.S. FDA IS ALLOWING CO TO MOVE FORWARD WITH U.S. IDE PIVOTAL STUDY OF ITS ISTENT SA TRABECULAR MICRO-BYPASS SYSTEM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below